Free Trial

Cantor Fitzgerald Issues Positive Forecast for ESPR Earnings

Esperion Therapeutics logo with Medical background
Remove Ads

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Equities research analysts at Cantor Fitzgerald increased their FY2025 EPS estimates for shares of Esperion Therapeutics in a research note issued on Wednesday, March 12th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biopharmaceutical company will post earnings per share of $0.12 for the year, up from their prior forecast of $0.05. Cantor Fitzgerald currently has a "Overweight" rating and a $8.00 price target on the stock. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share.

Several other research analysts have also recently commented on the stock. HC Wainwright reiterated a "buy" rating and issued a $16.00 target price on shares of Esperion Therapeutics in a report on Tuesday, March 4th. The Goldman Sachs Group initiated coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They set a "neutral" rating and a $4.00 price target for the company. Needham & Company LLC restated a "buy" rating and set a $6.00 price target on shares of Esperion Therapeutics in a report on Friday, December 13th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $4.00 price objective (down previously from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, Esperion Therapeutics has an average rating of "Hold" and an average target price of $6.75.

Get Our Latest Analysis on Esperion Therapeutics

Remove Ads

Esperion Therapeutics Price Performance

Shares of ESPR traded up $0.01 during mid-day trading on Friday, hitting $1.51. The company's stock had a trading volume of 1,398,618 shares, compared to its average volume of 5,956,761. The firm has a 50-day moving average price of $1.89 and a 200 day moving average price of $2.08. The stock has a market capitalization of $297.76 million, a price-to-earnings ratio of -2.37 and a beta of 1.04. Esperion Therapeutics has a fifty-two week low of $1.47 and a fifty-two week high of $3.94.

Institutional Trading of Esperion Therapeutics

A number of hedge funds have recently modified their holdings of the company. Cibc World Markets Corp acquired a new stake in Esperion Therapeutics during the 4th quarter worth approximately $39,000. Versor Investments LP acquired a new stake in Esperion Therapeutics during the 3rd quarter worth approximately $44,000. SJS Investment Consulting Inc. acquired a new stake in Esperion Therapeutics during the 4th quarter worth approximately $55,000. Crestline Management LP acquired a new stake in Esperion Therapeutics during the 4th quarter worth approximately $63,000. Finally, Summit Wealth Group LLC acquired a new stake in Esperion Therapeutics during the 3rd quarter worth approximately $66,000. 47.39% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

(Get Free Report)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Featured Articles

Earnings History and Estimates for Esperion Therapeutics (NASDAQ:ESPR)

Should You Invest $1,000 in Esperion Therapeutics Right Now?

Before you consider Esperion Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Esperion Therapeutics wasn't on the list.

While Esperion Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

7 Flying Car Stocks to Buy Before the Sector Really Takes Off
Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads